Hepatitis B virus reactivation in patients with solid tumors receiving systemic anticancer treatment

Annals of Oncology

Volumn 27, Issue 12, 2016, Pages 2172-2184

  Voican, C S ^a   Mir, Olivier ^b   Loulergue, P ^a   Dhooge, M ^a   Brezault, C ^a   Dreanic J ^a   Chaussade, S ^a   Pol, S ^a,c   Coriat, R ^a  

^a Sorbonne Paris Cité ^*  (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c INSTITUT PASTEUR   (France)

Author keywords

Chemotherapy; Hepatitis B reactivation; Immunotherapy; Monoclonal antibodies; Solid tumors; Tyrosine kinase inhibitors

Indexed keywords

ADEFOVIR DIPIVOXIL; ANTHRACYCLINE; CYCLOPHOSPHAMIDE; ENTECAVIR; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; IMATINIB; IRINOTECAN; LAMIVUDINE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; METHOTREXATE; MONOCLONAL ANTIBODY; PLATINUM DERIVATIVE; TAXANE DERIVATIVE; TENOFOVIR DISOPROXIL; VINORELBINE TARTRATE; ANTINEOPLASTIC AGENT; DOXORUBICIN; RITUXIMAB;

ANTIVIRAL THERAPY; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DRUG DOSE REGIMEN; HEPATITIS B VIRUS; HUMAN; INFORMATION PROCESSING; MOLECULARLY TARGETED THERAPY; NONHUMAN; PATHOPHYSIOLOGY; PATIENT SELECTION; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SCREENING TEST; SOLID MALIGNANT NEOPLASM; SYSTEMIC THERAPY; VIRUS CLASSIFICATION; VIRUS REACTIVATION; VIRUS REPLICATION; CHEMICALLY INDUCED; COMPLICATION; DRUG EFFECTS; GENETICS; HEPATITIS B; NEOPLASM; PATHOGENICITY; PATHOLOGY; VIROLOGY; VIRUS ACTIVATION;

ANTINEOPLASTIC AGENTS; DOXORUBICIN; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; NEOPLASMS; RITUXIMAB; VIRUS ACTIVATION;

EID: 85017387311     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/ANNONC/MDW414     Document Type: Review

References (90)

1. World Health Organization. Hepatitis B. World Health Organization Fact Sheet 204 (Revised July 2013). WHO Web site. 2013. http://who.int/inf-fs/en/fact204.html (15 July 2016, date last accessed)
2. Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine 2012; 30: 2212-2219
3. Liu CJ, Kao JH. Global perspective on the natural history of chronic hepatitis B: role of hepatitis B virus genotypes a to j. Semin Liver Dis 2013; 33: 97-102
4. Raimondo G, Allain JP, Brunetto MR et al. Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol 2008; 49: 652-657
5. Hoofnagle JH. Reactivation of hepatitis B. Hepatology 2009; 49: S156-S165
6. Yeo W, Chan HL. Hepatitis B virus reactivation associated with anti-neoplastic therapy. J Gastroenterol Hepatol 2012; 28: 31-37
7. Lok AS, Liang RH, Chiu EK et al. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 1991; 100: 182-188
8. Alexopoulos CG, Vaslamatzis M, Hatzidimitriou G. Prevalence of hepatitis B virus marker positivity and evolution of hepatitis B virus profile, during chemotherapy, in patients with solid tumours. Br J Cancer 1999; 81: 69-74
9. Maini MK, Boni C, Ogg GS et al. Direct ex vivo analysis of hepatitis B virus-specific CD8(!) T cells associated with the control of infection. Gastroenterology 1999; 117: 1386-1396
10. Thimme R, Wieland S, Steiger C et al. CD8(!) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol 2003; 77: 68-76
11. Rehermann B, Ferrari C, Pasquinelli C, Chisari FV. The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med 1996; 2: 1104-1108
12. Raimondo G, Caccamo G, Filomia R, Pollicino T. Occult HBV infection. Semin Immunopathol 2013; 35: 39-52
13. Hui CK, Bowden S, Jackson K et al. Clinical significance of intrahepatic hepatitis B virus covalently closed circular DNA in chronic hepatitis B patients who received cytotoxic chemotherapy. Blood 2005; 105: 2616-2617
14. Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 2005; 5: 215-229
15. Yeo W, Chan PK, Zhong S et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 2000; 62: 299-307
16. Jang JW, Choi JY, Bae SH et al. Transarterial chemo-lipiodolization can reactivate hepatitis B virus replication in patients with hepatocellular carcinoma. J Hepatol 2004; 41: 427-435
17. Hagiwara S, Sakurai T, Nishina S et al. Characteristic pattern of reactivation of hepatitis B virus during chemotherapy for solid cancers. Dig Dis 2012; 30: 541-546
18. Jang JW, Kwon JH, You CR et al. Risk of HBV reactivation according to viral status and treatment intensity in patients with hepatocellular carcinoma. Antivir Ther 2011; 16: 969-977
19. Ide Y, Ito Y, Takahashi S et al. Hepatitis B virus reactivation in adjuvant chemotherapy for breast cancer. Breast Cancer 2013; 20: 367-370
20. Groth CG, Backman L, Morales JM et al. Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation 1999; 67: 1036-1042
21. Coenen JJ, Koenen HJ, van Rijssen E et al. Rapamycin, not cyclosporine, permits thymic generation and peripheral preservation of CD4! CD25! FoxP3! T cells. Bone Marrow Transplant 2007; 39: 537-545
22. Teng CF, Wu HC, Tsai HW et al. Novel feedback inhibition of surface antigen synthesis by mammalian target of rapamycin (mTOR) signal and its implication for hepatitis B virus tumorigenesis and therapy. Hepatology 2011; 54: 1199-1207
23. Mizuno S, Yamagishi Y, Ebinuma H et al. Progressive liver failure induced by everolimus for renal cell carcinoma in a 58-year-old male hepatitis B virus carrier. Clin J Gastroenterol 2013; 6: 188-192
24. Sezgin Goksu S, Bilal S, Coskun HS. Hepatitis B reactivation related to everolimus. World J Hepatol 2013; 5: 43-45
25. Teplinsky E, Cheung D, Weisberg I et al. Fatal hepatitis B reactivation due to everolimus in metastatic breast cancer: case report and review of literature. Breast Cancer Res Treat 2013; 141: 167-172
26. Yao JC, Shah MH, Ito T et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011; 364: 514-523
27. Kim SG, Chun JM, Jin R et al. Living donor liver transplantation for acute hepatic failure caused by reactivation of hepatitis B virus infection after chemotherapy for hematologic malignancy: case reports. Transplant Proc 2010; 42: 843-845
28. Wang YD, Cui GH, Li M et al. Hepatitis B virus reactivation in a chronic myeloid leukemia patient treated with imatinib mesylate. Chin Med J (Engl) 2012; 125: 2636-2637
29. Lai GM, Yan SL, Chang CS, Tsai CY. Hepatitis B reactivation in chronic myeloid leukemia patients receiving tyrosine kinase inhibitor. World J Gastroenterol 2013; 19: 1318-1321
30. Ikeda K, Shiga Y, Takahashi A et al. Fatal hepatitis B virus reactivation in a chronic myeloid leukemia patient during imatinib mesylate treatment. Leuk Lymphoma 2006; 47: 155-157
31. Kang BW, Lee SJ, Moon JH et al. Chronic myeloid leukemia patient manifesting fatal hepatitis B virus reactivation during treatment with imatinib rescued by liver transplantation: case report and literature review. Int J Hematol 2009; 90: 383-387
32. Lakhani S, Davidson L, Priebat DA, Sherker AH. Reactivation of chronic hepatitis B infection related to imatinib mesylate therapy. Hepatol Int 2008; 2: 498-499
33. Seggewiss R, Lore K, Greiner E et al. Imatinib inhibits T-cell receptor-mediated Tcell proliferation and activation in a dose-dependent manner. Blood 2005; 105: 2473-2479
34. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167-185
35. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-662
36. Hwang JP, Somerfield MR, Alston-Johnson DE et al. Hepatitis B virus screening for patients with cancer before therapy: American Society of Clinical Oncology provisional clinical opinion update. J Clin Oncol 2015; 33: 2212-2220
37. Lee R, Vu K, Bell CM, Hicks LK. Screening for hepatitis B surface antigen before chemotherapy: current practice and opportunities for improvement. Curr Oncol 2010; 17: 32-38
38. Wang Y, Luo XM, Yang D et al. Testing for hepatitis B infection in prospective chemotherapy patients: a retrospective study. World J Gastroenterol 2013; 19: 923-930
39. Day FL, Link E, Thursky K, Rischin D. Current hepatitis B screening practices and clinical experience of reactivation in patients undergoing chemotherapy for solid tumors: a nationwide survey of medical oncologists. J Oncol Pract 2011; 7: 141-147
40. Zurawska U, Hicks LK, Woo G et al. Hepatitis B virus screening before chemotherapy for lymphoma: a cost-effectiveness analysis. J Clin Oncol 2012; 30: 3167-3173
41. Minuk GY, Uhanova J. Chronic hepatitis B infection in Canada. Can J Infect Dis 2001; 12: 351-356
42. Day FL, Karnon J, Rischin D. Cost-effectiveness of universal hepatitis B virus screening in patients beginning chemotherapy for solid tumors. J Clin Oncol 2011; 29: 3270-3277
43. Paul S, Saxena A, Terrin N et al. Hepatitis B virus reactivation and prophylaxis during solid tumor chemotherapy: a systematic review and meta-analysis. Ann Intern Med 2016; 164: 30-40
44. Kim MK, Ahn JH, Kim SB et al. Hepatitis B reactivation during adjuvant anthracycline-based chemotherapy in patients with breast cancer: a single institution's experience. Korean J Intern Med 2007; 22: 237-243
45. Clark FL, Drummond MW, Chambers S et al. Successful treatment with lamivudine for fulminant reactivated hepatitis B infection following intensive therapy for highgrade non-Hodgkin's lymphoma. Ann Oncol 1998; 9: 385-387
46. Ahmed A, Keeffe EB. Lamivudine therapy for chemotherapy-induced reactivation of hepatitis B virus infection. Am J Gastroenterol 1999; 94: 249-251
47. Cainelli F, Longhi MS, Concia E, Vento S. Failure of lamivudine therapy for chemotherapy-induced reactivation of hepatitis B. Am J Gastroenterol 2001; 96: 1651-1652
48. Jang JW, Choi JY, Bae SH et al. A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization. Hepatology 2006; 43: 233-240
49. Long M, Jia W, Li S et al. A single-center, prospective and randomized controlled study: can the prophylactic use of lamivudine prevent hepatitis B virus reactivation in hepatitis B s-antigen seropositive breast cancer patients during chemotherapy? Breast Cancer Res Treat 2011; 127: 705-712
50. Yun J, Kim KH, Kang ES et al. Prophylactic use of lamivudine for hepatitis B exacerbation in post-operative breast cancer patients receiving anthracycline-based adjuvant chemotherapy. Br J Cancer 2011; 104: 559-563
51. Dai MS, Wu PF, Shyu RY et al. Hepatitis B virus reactivation in breast cancer patients undergoing cytotoxic chemotherapy and the role of preemptive lamivudine administration. Liver Int 2004; 24: 540-546
52. Yeo W, Ho WM, Hui P et al. Use of lamivudine to prevent hepatitis B virus reactivation during chemotherapy in breast cancer patients. Breast Cancer Res Treat 2004; 88: 209-215
53. Marcellin P, Chang TT, Lim SG et al. Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2008; 48: 750-758
54. Mok TS, Zee B, Chan AT et al. A phase II study of gemcitabine plus oral etoposide in the treatment of patients with advanced nonsmall cell lung carcinoma. Cancer 2000; 89: 543-550
55. Allen MI, Deslauriers M, Andrews CW et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology 1998; 27: 1670-1677
56. Huang YH, Hsiao LT, Hong YC et al. Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B. J Clin Oncol 2013; 31: 2765-2772
57. Li HR, Huang JJ, Guo HQ et al. Comparison of entecavir and lamivudine in preventing hepatitis B reactivation in lymphoma patients during chemotherapy. J Viral Hepat 2011; 18: 877-883
58. Marcellin P, Heathcote EJ, Buti M et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008; 359: 2442-2455
59. Cheng JC, Liu MC, Tsai SY et al. Unexpectedly frequent hepatitis B reactivation by chemoradiation in postgastrectomy patients. Cancer 2004; 101: 2126-2133
60. Kitrinos KM, Corsa A, Liu Y et al. No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B. Hepatology 2014; 59: 434-42
61. Lau GK, Yiu HH, Fong DY et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology 2003; 125: 1742-1749
62. Huang H, Li X, Zhu J et al. Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial. JAMA 2014; 312: 2521-2530
63. Oksuzoglu B, Kilickap S, Yalcin S. Reactivation of hepatitis B virus infection in pancreatic cancer: a case report. Jpn J Clin Oncol 2002; 32: 543-545
64. Okagawa Y, Takada K, Hisai H et al. Successful treatment with entecavir for reactivation of hepatitis B virus following systemic chemotherapy in a hepatitis B surface antigen-negative patient with colorectal cancer. Intern Med 2014; 53: 1759-1762
65. Gonzalez-Aparicio M, Alzuguren P, Mauleon I et al. Oxaliplatin in combination with liver-specific expression of interleukin 12 reduces the immunosuppressive microenvironment of tumours and eradicates metastatic colorectal cancer in mice. Gut 2011; 60: 341-349
66. Eren OO, Artac M, Boruban MC et al. Chemotherapy-induced Hepatitis B virus reactivation in HbsAg positive cancer patients: a single center experience. Med Oncol 2009; 26: 386-392
67. Gattinoni L, Powell DJ, Jr, Rosenberg SA, Restifo NP. Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol 2006; 6: 383-393
68. Sistigu A, Viaud S, Chaput N et al. Immunomodulatory effects of cyclophosphamide and implementations for vaccine design. Semin Immunopathol 2011; 33: 369-383
69. Droz N, Gilardin L, Cacoub P et al. Kinetic profiles and management of hepatitis B virus reactivation in patients with immune-mediated inflammatory diseases. Arthritis Care Res (Hoboken) 2013; 65: 1504-1514
70. Ma B, Yeo W, Hui P et al. Acute toxicity of adjuvant doxorubicin and cyclophosphamide for early breast cancer-a retrospective review of Chinese patients and comparison with an historic Western series. Radiother Oncol 2002; 62: 185-189
71. Yeo W, Chan PK, Hui P et al. Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: a prospective study. J Med Virol 2003; 70: 553-561
72. Park SH, Bang SM, Cho EK et al. First-line chemotherapy with irinotecan plus capecitabine for advanced colorectal cancer. Oncology 2004; 66: 353-357
73. Nagami K, Kawashima Y, Kuno H et al. In vitro cytotoxicity assay to screen compounds for apoptosis-inducing potential on lymphocytes and neutrophils. J Toxicol Sci 2002; 27: 191-203
74. Plate JM, Plate AE, Shott S et al. Effect of gemcitabine on immune cells in subjects with adenocarcinoma of the pancreas. Cancer Immunol Immunother 2005; 54: 915-925
75. Alvino E, Fuggetta MP, Tricarico M, Bonmassar E. 20-20-difluorodeoxycytidine: in vitro effects on cell-mediated immune response. Anticancer Res 1998; 18: 3597-3602
76. Cheong K, Li J, Karapetis CS. Gemcitabine and reactivation of hepatitis B. Med Oncol 2003; 20: 385-388
77. Kapetanovic MC, Saxne T, Sjoholm A et al. Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis. Rheumatology (Oxford) 2006; 45: 106-111
78. Johnston A, Gudjonsson JE, Sigmundsdottir H et al. The anti-inflammatory action of methotrexate is not mediated by lymphocyte apoptosis, but by the suppression of activation and adhesion molecules. Clin Immunol 2005; 114: 154-163
79. Higashiyama H, Harabayashi T, Shinohara N et al. Reactivation of hepatitis in a bladder cancer patient receiving chemotherapy. Int Urol Nephrol 2007; 39: 461-463
80. Ito S, Nakazono K, Murasawa A et al. Development of fulminant hepatitis B (precore variant mutant type) after the discontinuation of low-dose methotrexate therapy in a rheumatoid arthritis patient. Arthritis Rheum 2001; 44: 339-342
81. Gwak GY, Koh KC, Kim HY. Fatal hepatic failure associated with hepatitis B virus reactivation in a hepatitis B surface antigen-negative patient with rheumatoid arthritis receiving low dose methotrexate. Clin Exp Rheumatol 2007; 25: 888-889
82. Watanabe K, Takase K, Ohno S et al. Reactivation of hepatitis B virus in a hepatitis B surface antigen-negative patient with rheumatoid arthritis treated with methotrexate. Mod Rheumatol 2012; 22: 470-473
83. Tange S, Scherer MN, Graeb C et al. The antineoplastic drug Paclitaxel has immunosuppressive properties that can effectively promote allograft survival in a rat heart transplant model. Transplantation 2002; 73: 216-223
84. Tange S, Scherer MN, Graeb C et al. Paclitaxel saves rat heart allografts from rejection by inhibition of the primed anti-donor humoral and cellular immune response: implications for transplant patients with cancer. Transpl Int 2003; 16: 471-475
85. Yeo W, Mok TS, Tse KK et al. Phase II study of docetaxel and epirubicin in Chinese patients with metastatic breast cancer. Anticancer Drugs 2002; 13: 655-662
86. Leong SS, Wee J, Tay MH et al. Paclitaxel, carboplatin, and gemcitabine in metastatic nasopharyngeal carcinoma: a Phase II trial using a triplet combination. Cancer 2005; 103: 569-575
87. Ferraro C, Quemeneur L, Prigent AF et al. Anthracyclines trigger apoptosis of both G0-G1 and cycling peripheral blood lymphocytes and induce massive deletion of mature T and B cells. Cancer Res 2000; 60: 1901-1907
88. Hsu CH, Hsu HC, Chen HL et al. Doxorubicin activates hepatitis B virus (HBV) replication in HBV-harboring hepatoblastoma cells. A possible novel mechanism of HBV reactivation in HBV carriers receiving systemic chemotherapy. Anticancer Res 2004; 24: 3035-3040
89. Xu L, Tu Z, Xu G et al. Epirubicin directly promotes hepatitis B virus (HBV) replication in stable HBV-expressing cell lines: a novel mechanism of HBV reactivation following anticancer chemotherapy. Mol Med Rep 2014; 9: 1345-1350
90. Yeo W, Lam KC, Zee B et al. Hepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy. Ann Oncol 2004; 15: 1661-1666